MicuRx Pairs US Phase II Trial of Novel Antibiotic with China Test

MicuRx Pharma, a US-China company, was granted FDA approval to begin a US Phase II trial of its lead molecule, MRX-I, a novel oral antibiotic for drug-resistant Gram-positive infections. MicuRx, which has already begun a parallel Phase II trial of the antibiotic in China, believes its antibiotic is both safer and more effective than others in the class. Headquartered in the San Francisco area, MicuRx also operates a lab in Shanghai’s Zhangjiang High-Tech Park. More details.... Share this with colleagues: // //